Patents by Inventor Roberto Pellicciari

Roberto Pellicciari has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions
    Patent number: 8546365
    Abstract: The present invention relates to compounds of formula (I): wherein R is hydrogen or alpha-hydroxy, the hydroxyl group in position 7 is in the alpha or beta position; and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof.
    Type: Grant
    Filed: April 7, 2011
    Date of Patent: October 1, 2013
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: Roberto Pellicciari, Stefano Fiorucci, Mark Pruzanski
  • TGR5 modulators and methods of use thereof
    Patent number: 8445472
    Abstract: The invention relates to compounds of Formula A: or a salt, solvate, hydrate, or prodrug thereof. The compounds of Formula A are TGR5 modulators useful for the treatment of various diseases, including metabolic disease, inflammatory disease, liver disease, autoimmune disease, cardiac disease, kidney disease, cancer, and gastrointestinal disease.
    Type: Grant
    Filed: December 7, 2011
    Date of Patent: May 21, 2013
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventor: Roberto Pellicciari
  • 23-substituted bile acids as TGR5 modulators and methods of use thereof
    Patent number: 8410083
    Abstract: The invention relates to compounds of Formula A: (A) or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. The compounds of Formula A are TGR5 modulators useful for the treatment of various diseases, including obesity, insulin sensitivity, inflammation, cholestasis, and bile desaturation.
    Type: Grant
    Filed: January 18, 2008
    Date of Patent: April 2, 2013
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventor: Roberto Pellicciari
  • Thiazolyl- and Oxazolyl-Isoquinolinones and Methods for Using Them
    Publication number: 20130059843
    Abstract: The present invention relates to substituted thiazolyl- and oxazolyl-isoquinolinones that act, for example, as modulators of poly(ADP-ribose) polymerase (PARP). The present invention also relates to processes for the preparation of substituted thiazolyl- and oxazolyl-isoquinolinones and to their use in treating various diseases and disorders.
    Type: Application
    Filed: October 18, 2012
    Publication date: March 7, 2013
    Inventors: Roberto Pellicciari, Flavio Moroni, Adam Gilbert
  • Steroids as agonists for FXR
    Patent number: 8377916
    Abstract: The invention relates to compounds of formula (I): wherein R is ethyl, propyl or allyl, and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof. The compounds of formula (I) are useful as FXR agonists.
    Type: Grant
    Filed: November 3, 2011
    Date of Patent: February 19, 2013
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventor: Roberto Pellicciari
  • Bile Acid Derivatives As FXR Ligands For The Prevention Or Treatment Of FXR-Mediated Diseases Or Conditions
    Publication number: 20120283234
    Abstract: The present invention relates to compounds of formula (I): wherein R is hydrogen or alpha-hydroxy, the hydroxyl group in position 7 is in the alpha or beta position; and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof.
    Type: Application
    Filed: April 7, 2011
    Publication date: November 8, 2012
    Applicant: Intercept Pharmaceuticals, Inc.
    Inventors: Roberto Pellicciari, Stefano Fiorucci, Mark Pruzanski
  • Thiazolyl-and oxazolyl-isoquinolinones and methods for using them
    Patent number: 8299090
    Abstract: The present invention relates to substituted thiazolyl- and oxazoyl-isoquinolinones that act, for example, as modulators of poly(ADP-ribose) polymerase (PARP). The present invention also relates to processes for the preparation of substituted thiazolyl- and oxazolyl-isoquinolinones and to their use in treating various diseases and disorders.
    Type: Grant
    Filed: June 18, 2009
    Date of Patent: October 30, 2012
    Inventors: Roberto Pellicciari, Flavio Moroni, Adam Matthew Gilbert
  • TGR5 Modulators and Methods of Use Thereof
    Publication number: 20120115832
    Abstract: The invention relates to compounds of Formula A: or a salt, solvate, hydrate, or prodrug thereof. The compounds of Formula A are TGR5 modulators useful for the treatment of various diseases, including metabolic disease, inflammatory disease, liver disease, autoimmune disease, cardiac disease, kidney disease, cancer, and gastrointestinal disease.
    Type: Application
    Filed: December 7, 2011
    Publication date: May 10, 2012
    Applicant: Intercept Pharmaceuticals, Inc.
    Inventor: Roberto Pellicciari
  • Steroids as Agonists for FXR
    Publication number: 20120053163
    Abstract: The invention relates to compounds of formula (I): wherein R is ethyl, propyl or allyl, and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof. The compounds of formula (I) are useful as FXR agonists.
    Type: Application
    Filed: November 3, 2011
    Publication date: March 1, 2012
    Applicant: Intercept Pharmaceuticals, Inc.
    Inventor: Roberto Pellicciari
  • TGR5 modulators and methods of use thereof
    Patent number: 8114862
    Abstract: The invention relates to compounds of Formula A: or a salt, solvate, hydrate, or prodrug thereof. The compounds of Formula A are TGR5 modulators useful for the treatment of various diseases, including metabolic disease, inflammatory disease, liver disease, autoimmune disease, cardiac disease, kidney disease, cancer, and gastrointestinal disease.
    Type: Grant
    Filed: November 19, 2009
    Date of Patent: February 14, 2012
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventor: Roberto Pellicciari
  • Steroids as agonists for FXR
    Patent number: 8058267
    Abstract: The invention relates to compounds of formula (I): wherein R is ethyl and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof. The compounds of formula (I) are useful as FXR agonists.
    Type: Grant
    Filed: August 25, 2009
    Date of Patent: November 15, 2011
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventor: Roberto Pellicciari
  • TGR5 Modulators and Methods of Use Thereof
    Publication number: 20110263555
    Abstract: The invention relates to compounds of Formula (A): (A) or a salt, solvate, hydrate, or amino acid conjugate thereof. The compounds of formula A are TGR5 modulators useful for the prevention and treatment of disease.
    Type: Application
    Filed: November 19, 2009
    Publication date: October 27, 2011
    Inventor: Roberto Pellicciari
  • THIENO[2,3-C] ISOQUINOLINES FOR USE AS INHIBITORS OF PARP
    Publication number: 20110237617
    Abstract: The present invention relates to compounds for the inhibition of poly(ADP-ribose) polymerase (PARP). In some embodiments, the compounds have the Formula: wherein the constituent variables are as defined herein. The invention further provides methods for the use of the compounds disclosed herein.
    Type: Application
    Filed: November 2, 2010
    Publication date: September 29, 2011
    Inventors: ROBERTO PELLICCIARI, FLAVIO MORONI
  • Process for preparing 3a(?)-7a(?)-dihydroxy-6a(?)-alkyl-5?-cholanic acid
    Patent number: 7994352
    Abstract: Process for preparing 3?-7?(?)-dihydroxy-6?(?)-alkyl-5?-cholanic acid (I) in which R is a linear or branched C1-C5 alkyl and the relative intermediates 3?-hydroxy-6?-alkyl-7-keto-5?-cholanic (VIII) and 3?-hydroxy-6?-alkyl-7-keto-5?-cholanic (IX).
    Type: Grant
    Filed: May 19, 2006
    Date of Patent: August 9, 2011
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: Massimo Ferrari, Roberto Pellicciari
  • TGR5 Modulators And Methods Of Use Thereof
    Publication number: 20110172198
    Abstract: The invention relates to compounds of Formula A: (A) or a salt, solvate, or hydrate thereof. The compounds of formula A are TGR5 modulators useful for the treatment of disease.
    Type: Application
    Filed: July 30, 2009
    Publication date: July 14, 2011
    Applicant: Intercept Pharmaceuticals, Inc.
    Inventor: Roberto Pellicciari
  • Inhibitors of Kynurenine Aminotransferase and Uses Therefor
    Publication number: 20110144064
    Abstract: Provided herein are methods of decreasing a level of kynurenic acid in a cell and of treating a pathophysiological condition in a subject associated with an increase in kynurenic acid in a subject. In these methods the inhibitory action of dicarboxylic acids or derivatives or analogs thereof are effective to inhibit activity of kynurenine aminotransferase II. Also provided is a method of screening for potential inhibitory compounds for kynurenine aminotransferase II. The dicarboxylic acids or derivatives or analogs thereof may have the structural formula, where R1 is H, NH2 or NHCH3, R2 is H or CH3, n is 0 to 14, and X is —COOH, CH2OH, —PO3H2, —SO3H, or —SO3H; or a pharmacologically acceptable salt.
    Type: Application
    Filed: November 30, 2006
    Publication date: June 16, 2011
    Inventors: Robert Schwarcz, Roberto Pellicciari, Timothy Gately
  • Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions
    Patent number: 7932244
    Abstract: The present invention relates to compounds of formula (I): wherein R is hydrogen or alpha-hydroxy, the hydroxyl group in position 7 is in the alpha or beta position; and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof.
    Type: Grant
    Filed: June 27, 2007
    Date of Patent: April 26, 2011
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: Roberto Pellicciari, Stefano Fiorucci, Mark Pruzanski
  • 23-Substituted Bile Acids as TGR5 Modulators and Methods of Use Thereof
    Publication number: 20110003782
    Abstract: The invention relates to compounds of Formula A: (A) or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. The compounds of Formula A are TGR5 modulators useful for the treatment of various diseases, including obesity, insulin sensitivity, inflammation, cholestasis, and bile desaturation.
    Type: Application
    Filed: January 18, 2008
    Publication date: January 6, 2011
    Inventor: Roberto Pellicciari
  • Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions
    Patent number: 7858608
    Abstract: The present invention relates to compounds of formula (I) wherein: R1 is hydrogen or an alkyl group; R2 is hydrogen or a halogen, nitro, alkyloxy, amino or carboxy group; Y is CH2, oxygen or sulfur; n is an integer from 1 to 4, and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof for the treatment of FXR-mediated diseases or conditions.
    Type: Grant
    Filed: May 4, 2009
    Date of Patent: December 28, 2010
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: Roberto Pellicciari, Stefano Fiorucci, Mark Pruzanski
  • Thieno[2,3-c] isoquinolines for use as inhibitors of PARP
    Patent number: 7825129
    Abstract: The present invention relates to compounds for the inhibition of poly(ADP-ribose) polymerase (PARP). In some embodiments, the compounds have the Formula: wherein the constituent variables are as defined herein. The invention further provides methods for the use of the compounds disclosed herein.
    Type: Grant
    Filed: November 1, 2005
    Date of Patent: November 2, 2010
    Inventors: Roberto Pellicciari, Flavio Moroni